SLDB · NASDAQ · Biotechnology

Solid Biosciences

Advancing gene therapy candidates for Duchenne and other rare neuromuscular and cardiac diseases.

$9.77
After-hours close−0.01 (−0.10%)
At close$9.78(−3.46%)
DateEstimateReportedSurprise
Nov 2026−$0.37
Aug 2026−$0.46−$0.38+17.8%
May 2026−$0.40−$0.52−30.0%
Mar 2026−$0.51−$0.50+2.0%
Nov 2025−$0.42−$0.48−14.3%

The latest year is open to everyone — the 36 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
Apr 2022
Mar 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Nov 2020
Aug 2020
May 2020
Mar 2020
Nov 2019
Aug 2019
May 2019
Mar 2019
Nov 2018
Aug 2018
May 2018
Mar 2018
Jan 2018
Jun 2017
Mar 2017
Dec 2016
Mar 2016
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Nov 2, 2026−$0.37
Aug 6, 2026−$0.46−$0.38+17.8%
May 12, 2026−$0.40−$0.52−30.0%
Mar 19, 2026−$0.51−$0.50+2.0%
Nov 3, 2025−$0.42−$0.48−14.3%

The latest year is open to everyone — the 36 quarters behind it read with an account.

Sign in
Aug 12, 2025
May 15, 2025
Mar 6, 2025
Nov 6, 2024
Aug 13, 2024
May 15, 2024
Mar 13, 2024
Nov 8, 2023
Aug 14, 2023
May 11, 2023
Mar 23, 2023
Nov 10, 2022
Aug 11, 2022
Apr 27, 2022
Mar 14, 2022
Nov 3, 2021
Aug 16, 2021
May 14, 2021
Mar 15, 2021
Nov 5, 2020
Aug 6, 2020
May 7, 2020
Mar 12, 2020
Nov 12, 2019
Aug 14, 2019
May 13, 2019
Mar 13, 2019
Nov 13, 2018
Aug 10, 2018
May 10, 2018
Mar 29, 2018
Jan 29, 2018
Jun 30, 2017
Mar 31, 2017
Dec 31, 2016
Mar 31, 2016